Shire-Nps Pharmaceuticals (NASDAQ: NPSP) and Juno Therapeutics (NASDAQ:JUNO) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.


How to Become a New Pot Stock Millionaire

This table compares Shire-Nps Pharmaceuticals and Juno Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Shire-Nps Pharmaceuticals -2.96% -5.98% -2.77%
Juno Therapeutics -390.66% -39.24% -29.31%

Analyst Ratings

This is a summary of recent recommendations and price targets for Shire-Nps Pharmaceuticals and Juno Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shire-Nps Pharmaceuticals 0 0 0 0 N/A
Juno Therapeutics 0 15 2 0 2.12

Juno Therapeutics has a consensus target price of $56.21, suggesting a potential downside of 35.36%.

Earnings & Valuation

This table compares Shire-Nps Pharmaceuticals and Juno Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Shire-Nps Pharmaceuticals N/A N/A N/A ($0.08) N/A
Juno Therapeutics $111.87 million 90.26 -$245.58 million ($5.38) -16.16

Shire-Nps Pharmaceuticals has higher earnings, but lower revenue than Juno Therapeutics. Juno Therapeutics is trading at a lower price-to-earnings ratio than Shire-Nps Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

70.2% of Juno Therapeutics shares are owned by institutional investors. 15.1% of Juno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

About Shire-Nps Pharmaceuticals

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

About Juno Therapeutics

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive News & Ratings for Shire-Nps Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire-Nps Pharmaceuticals and related companies with's FREE daily email newsletter.